ADIL,KTTA Stock Price and Quote

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: LNAI APRE BCDA BIVI CALC CVM GOVX KAPA KPRX NEUP

| Held by: VXF

Index	-
Market Cap	6.08M
Enterprise Value	1.50M
Income	-7.77M
Sales	0.00M
Book/sh	2.46
Cash/sh	2.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Jul 27, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.13
P/C	1.33
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.18
Current Ratio	3.18
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-9.90
EPS next Y	-1.53
EPS next Q	-1.02
EPS this Y	67.76%
EPS next Y	60.23%
EPS next 5Y	47.67%
EPS past 3/5Y	88.55% 53.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	75.60%
Sales Y/Y TTM	-
EPS Q/Q	82.68%
Sales Q/Q	-
Earnings	May 11 BMO
EPS/Sales Surpr.	45.79% -

Insider Own	0.96%
Insider Trans	119.07%
Inst Own	18.68%
Inst Trans	-1.17%
ROA	-179.08%
ROE	-265.94%
ROIC	-209.05%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.65%
SMA50	23.96%
SMA200	-40.01%
Trades

Shs Outstand	2.19M
Shs Float	2.17M
Short Float	10.64%
Short Ratio	0.49
Short Interest	0.23M
52W High	18.90 -85.29%
52W Low	1.31 112.21%
Volatility	7.44% 17.02%
ATR (14)	0.28
RSI (14)	57.53
Beta	1.43
Rel Volume	0.11
Avg Volume	472.41K
Volume	51,046

Perf Week	-4.14%
Perf Month	30.52%
Perf Quarter	78.21%
Perf Half Y	-53.08%
Perf YTD	-49.45%
Perf Year	-72.88%
Perf 3Y	-97.80%
Perf 5Y	-99.84%
Perf 10Y	-
Recom	1.00
Target Price	18.67
Prev Close	2.80
Price	2.78
Change	-0.71%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-30-18	Initiated	Maxim Group	Buy	$5
Oct-11-18	Initiated	Dawson James	Buy

Jun-16-26 08:00AM	Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing (GlobeNewswire) -10.88%
Jun-11-26 01:04PM	ADIL Stock Eyes Best Day In Over 5 Years Major Pipeline Overhaul And $64M Raise Fuel Rally (Stocktwits) +37.96%
11:43AM	Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing (GlobeNewswire)
May-11-26 08:30AM	Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-26 09:07AM	Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045 (GlobeNewswire)
08:47AM	Loading…
Apr-27-26 08:47AM	Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program (GlobeNewswire)
Apr-22-26 09:35AM	Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial (GlobeNewswire)
Mar-24-26 09:07AM	Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans (GlobeNewswire) -8.15%
Mar-06-26 08:00AM	Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire) -7.11%
Mar-03-26 08:17AM	Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement (GlobeNewswire) -7.29%
08:02AM	EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million (Benzinga)
Feb-24-26 09:00AM	Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement (GlobeNewswire)
Feb-23-26 08:30AM	Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One (GlobeNewswire)
Feb-17-26 09:00AM	Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire) -5.26%
Feb-04-26 09:35AM	Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04 (GlobeNewswire) -25.79%
04:05PM	Loading…
Feb-03-26 04:05PM	Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement (GlobeNewswire)
Jan-14-26 09:00AM	Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 (GlobeNewswire)
Jan-06-26 09:40AM	Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-26-25 08:00AM	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds (GlobeNewswire)
Nov-14-25 08:30AM	Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-17-25 09:00AM	Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show (GlobeNewswire)
Oct-09-25 08:30AM	Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution (GlobeNewswire)
Sep-30-25 09:42AM	CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls (The Fly) +6.35%
Sep-16-25 08:03AM	Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder (Benzinga)
08:00AM	Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 (GlobeNewswire)
Sep-03-25 08:30AM	Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule (GlobeNewswire)
Sep-01-25 12:00PM	All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy (Zacks)
Aug-20-25 08:30AM	Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments (GlobeNewswire)
Aug-14-25 08:30AM	Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-06-25 08:00AM	Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting (GlobeNewswire)
08:30AM	Loading…
Jul-16-25 08:30AM	Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement (GlobeNewswire) +10.05%
Jul-10-25 12:00PM	Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why (Zacks) +28.61%
Jul-09-25 08:30AM	Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045 (GlobeNewswire)
06:15AM	Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck (GlobeNewswire)
Jun-25-25 08:30AM	Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply (GlobeNewswire) +7.28%
Jun-17-25 08:00AM	Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering (GlobeNewswire) -25.99%
Jun-16-25 08:00AM	Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting (GlobeNewswire) -7.14%
Jun-11-25 08:00AM	Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04 (GlobeNewswire) -23.77%
07:30AM	EXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial (Benzinga)
May-15-25 08:30AM	Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-13-25 08:30AM	Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study (GlobeNewswire)
May-08-25 08:30AM	Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration (GlobeNewswire)
08:02AM	EXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program (Benzinga)
May-02-25 11:48AM	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds (GlobeNewswire) -14.10%
May-01-25 08:30AM	Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders (GlobeNewswire) +13.04%
08:02AM	EXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders (Benzinga)
Mar-04-25 08:30AM	Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-25 09:00AM	Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04 (GlobeNewswire) +20.64%
08:30AM	EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder (Benzinga)
Feb-19-25 09:00AM	Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies (GlobeNewswire)
Feb-12-25 09:00AM	Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders (GlobeNewswire)
08:30AM	EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders (Benzinga)
Jan-29-25 09:00AM	Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
08:31AM	EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder (Benzinga)
Dec-03-24 08:30AM	Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations (GlobeNewswire)
08:00AM	EXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations (Benzinga)
Nov-25-24 12:00PM	Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-14-24 08:30AM	Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire) +15.04%
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder (Benzinga)
Nov-13-24 08:30AM	Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:30AM	Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer (GlobeNewswire)
Oct-23-24 09:00AM	Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference (GlobeNewswire) -8.55%
Oct-17-24 09:00AM	Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company's Genetic Diagnostic for Addiction Treatment (GlobeNewswire) -5.82%
08:30AM	EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate (Benzinga)
Oct-15-24 09:00AM	Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery (GlobeNewswire)
Sep-19-24 08:30AM	Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
Sep-04-24 09:00AM	Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-14-24 08:30AM	Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-13-24 09:00AM	Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04 (GlobeNewswire)
08:30AM	EXCLUSIVE: Adial Pharmaceuticals Advances Regulatory Strategy For Companion Diagnostic Genetic Test For Its Lead Program For Alcohol Use Disorder (Benzinga)
Aug-07-24 09:00AM	Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
08:30AM	EXCLUSIVE: Adial Pharmaceuticals' Last Patient Dosed in Pharmacokinetics Study of AD04 For Alcohol Use Disorder, Data Expected In Q4 (Benzinga)
Jul-31-24 08:30AM	Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 (GlobeNewswire)
Jul-23-24 08:30AM	Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire) +23.58%
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Moves Forward To Second Cohort In Pharmacokinetics Study of AD04 For Alcohol Use Disorder (Benzinga)
Jun-27-24 05:52AM	ADIL Stock Earnings: Adial Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Jun-20-24 08:30AM	Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder (GlobeNewswire) -13.39%
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder (Benzinga)
Jun-06-24 07:00AM	MicroCap Rodeo's Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies (ACCESSWIRE)
Jun-05-24 03:17PM	Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025 (InvestorPlace)
08:30AM	Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder (GlobeNewswire)
08:00AM	EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder (Benzinga)
May-29-24 08:30AM	Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th (GlobeNewswire)
May-15-24 09:54AM	ADIL Stock Earnings: Adial Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
08:30AM	Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-22-24 10:00AM	EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent (Benzinga)
08:30AM	Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office (GlobeNewswire)
Apr-10-24 11:53AM	Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today? (InvestorPlace) +106.19%
08:30AM	Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder (GlobeNewswire)
Apr-02-24 08:30AM	Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-24 07:00PM	Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds (GlobeNewswire) +59.80% -15.64%
Feb-28-24 09:30AM	Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office (GlobeNewswire) +85.50%
Feb-15-24 09:00AM	Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20 (ACCESSWIRE)
Feb-13-24 09:15AM	Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office (GlobeNewswire) +8.72%
Jan-18-24 08:30AM	Adial Announces Appointment of Tony Goodman as Chief Operating Officer (GlobeNewswire)
Dec-20-23 09:00AM	Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate (GlobeNewswire)
Nov-29-23 04:05PM	Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement (GlobeNewswire)
Nov-14-23 05:02PM	Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.46%
Oct-31-23 08:30AM	Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss New Aspects in Substance Use Treatment at The Annual International Society of Addiction Medicine Conference (GlobeNewswire)
Oct-30-23 12:00PM	All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy (Zacks)

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

CEOMr. Cary John Claiborne MBA

C.P.A.Mr. Vinay Shah A.C.A.

Chief Legal OfficerMr. John R. Martin J.D.

Vice President of Corporate DevelopmentMr. Andrew Taubman

Chief Development Officer & DirectorDr. Matthew Davidson Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coastlands Capital LP	10% Owner	Jun 29 '26	Buy	2.60	25,000	65,000	373,322	Jul 01 10:30 AM

KTTA Pasithea Therapeutics Corp daily Stock Chart

Peers: BCTX CLRB JSPR LGVN MRKR NXTC PLUR TPST TRAW VTGN

| Held by: PSIL VXF

Index	-
Market Cap	16.45M
Enterprise Value	-34.05M
Income	-19.73M
Sales	0.00M
Book/sh	2.20
Cash/sh	1.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Sep 15, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.22
P/C	0.33
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	35.40
Current Ratio	35.40
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.07
EPS next Y	-1.01
EPS next Q	-0.16
EPS this Y	73.88%
EPS next Y	-32.89%
EPS next 5Y	23.55%
EPS past 3/5Y	35.92% -117.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	80.42%
Sales Y/Y TTM	-
EPS Q/Q	92.68%
Sales Q/Q	-
Earnings	Jun 03
EPS/Sales Surpr.	0.00% -

Insider Own	8.48%
Insider Trans	3.66%
Inst Own	56.26%
Inst Trans	-4.31%
ROA	-55.58%
ROE	-58.22%
ROIC	-36.00%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.14%
SMA50	-24.00%
SMA200	-37.64%
Trades

Shs Outstand	33.41M
Shs Float	30.58M
Short Float	0.94%
Short Ratio	0.34
Short Interest	0.29M
52W High	2.06 -76.10%
52W Low	0.28 75.23%
Volatility	7.03% 10.84%
ATR (14)	0.05
RSI (14)	34.13
Beta	0.29
Rel Volume	0.21
Avg Volume	833.69K
Volume	174,626

Perf Week	-10.44%
Perf Month	-15.10%
Perf Quarter	-31.61%
Perf Half Y	-49.24%
Perf YTD	-61.83%
Perf Year	-28.72%
Perf 3Y	-94.66%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	3.00
Prev Close	0.50
Price	0.49
Change	-1.52%

Jul-08-26 07:02AM	Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit (GlobeNewswire)
Jun-30-26 07:00AM	Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion (GlobeNewswire)
Jun-16-26 07:00AM	Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial (GlobeNewswire) -8.93%
Jun-15-26 07:02AM	Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference (GlobeNewswire) -5.26%
Jun-02-26 07:02AM	Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) -9.79%
07:01AM	Loading…
May-04-26 07:01AM	Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Apr-20-26 07:01AM	Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) (GlobeNewswire)
Apr-01-26 07:01AM	Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity (GlobeNewswire)
Feb-17-26 07:01AM	Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-26 07:01AM	Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines (GlobeNewswire)
Dec-02-25 07:00AM	Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock (GlobeNewswire)
Dec-01-25 08:38AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) -21.09%
Nov-28-25 09:20AM	Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock (GlobeNewswire) +38.68%
Nov-25-25 07:00AM	Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS (GlobeNewswire) +14.78%
Nov-24-25 07:00AM	Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data (GlobeNewswire) +45.33%
12:35PM	Loading…
Nov-21-25 12:35PM	Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients (GlobeNewswire) -29.58%
Nov-20-25 04:01PM	Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study (GlobeNewswire) -12.78%
Nov-04-25 07:03AM	Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire) -5.87%
Sep-16-25 07:03AM	Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire)
Sep-08-25 07:01AM	Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire)
Aug-29-25 08:39AM	Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-28-25 07:02AM	Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +11.76%
Jul-31-25 07:01AM	Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients (GlobeNewswire)
Jun-11-25 07:02AM	Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board (GlobeNewswire)
Jun-02-25 08:02AM	Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 (GlobeNewswire)
May-20-25 07:01AM	Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases (GlobeNewswire)
May-14-25 07:02AM	Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site (GlobeNewswire) +11.07%
May-07-25 05:00PM	Pasithea Therapeutics Announces Closing of $5 Million Public Offering (GlobeNewswire) -25.66% -15.04%
11:35AM	Pasithea Therapeutics 3.57M share Secondary priced at $1.40 (TipRanks)
May-06-25 11:10AM	Pasithea Therapeutics Announces Pricing of $5 Million Public Offering (GlobeNewswire) +7.04%
07:03AM	Loading…
07:03AM	Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 (GlobeNewswire)
Apr-29-25 07:02AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients (GlobeNewswire)
Apr-24-25 07:02AM	Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting (GlobeNewswire) +5.52%
Apr-10-25 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire) +46.79%
Mar-24-25 06:59AM	Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference (GlobeNewswire)
Feb-05-25 06:59AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire) +31.73%
Jan-14-25 08:02AM	Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 (GlobeNewswire)
Nov-20-24 07:02AM	Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-26-24 06:44PM	Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +52.15%
07:02AM	Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer (GlobeNewswire)
Sep-09-24 08:01AM	Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies (GlobeNewswire)
Sep-03-24 08:02AM	Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board (GlobeNewswire) +6.57%
Aug-28-24 09:11AM	Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Jun-25-24 12:52PM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q4 2023 (InvestorPlace) +6.64%
Jun-13-24 06:59AM	Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial (GlobeNewswire)
May-28-24 06:59AM	Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting (GlobeNewswire)
May-15-24 09:53AM	KTTA Stock Earnings: Pasithea Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-29-24 07:59AM	Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-24-24 07:59AM	Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers (GlobeNewswire)
Apr-15-24 11:00AM	11 Undervalued Stocks for Less Than $50 in April 2024 (Investopedia)
Feb-13-24 07:59AM	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 (GlobeNewswire) +8.95%
Jan-08-24 07:59AM	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position (GlobeNewswire) +5.03%
Jan-02-24 08:35AM	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients (GlobeNewswire) +8.78%
Dec-28-23 05:00PM	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 (GlobeNewswire) -5.13%
Dec-19-23 05:19PM	Pasithea Therapeutics Announces Results from 2023 Annual Meeting (GlobeNewswire) -6.06% -13.61%
Dec-13-23 09:03AM	Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? (InvestorPlace)
Dec-11-23 11:18AM	Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? (InvestorPlace) +47.42%
08:01AM	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models (GlobeNewswire)
Nov-29-23 04:27PM	Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) +6.63% -7.91%
07:59AM	Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development (GlobeNewswire)
Nov-09-23 07:59AM	Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 5 1 Integrin for the Treatment of both Sporadic and Familial ALS (GlobeNewswire)
Sep-14-23 08:30AM	Pasithea Therapeutics Corp. Announces Final Results of Tender Offer (GlobeNewswire)
Sep-07-23 04:14PM	Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -13.18%
Aug-01-23 07:59AM	Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival and motor function (GlobeNewswire)
Jul-31-23 06:00AM	The Psychedelics Stock Universe Is Shrinking, Despite the Hype (Bloomberg)
Jul-20-23 08:43AM	Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash (GlobeNewswire) +25.88%
08:40AM	Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. (GlobeNewswire)
Jul-13-23 09:14AM	Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood (Exec Edge)
Jun-30-23 09:28AM	Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors (GlobeNewswire)
Jun-29-23 02:50PM	Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +11.24%
08:29AM	Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004 (GlobeNewswire)
Jun-06-23 04:30PM	Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc. (GlobeNewswire)
Jun-05-23 09:00AM	Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +25.00%
Jun-01-23 07:57AM	Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference (GlobeNewswire)
May-14-23 08:13AM	Pasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022) (Simply Wall St.)
May-03-23 08:26AM	Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire)
Mar-02-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting (GlobeNewswire)
Feb-23-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) (GlobeNewswire) -5.64%
Feb-16-23 07:30AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award (GlobeNewswire)
Jan-18-23 08:00AM	Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004 (GlobeNewswire)
Dec-14-22 05:18PM	Majority of Stockholders Support Pasithea Directors at Special Meeting (GlobeNewswire)
Dec-12-22 07:00AM	Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group (GlobeNewswire) -8.22%
Dec-07-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Dec-06-22 08:00AM	Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference (GlobeNewswire)
Nov-28-22 07:05PM	Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time (GlobeNewswire)
Nov-22-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Oct-27-22 09:50AM	A New BioTech Research Race Is Focused On Improving Life For MS Patients (News Direct)
Oct-17-22 08:00AM	Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium (GlobeNewswire) -11.20%
Oct-14-22 09:48AM	Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive (Benzinga)
Oct-13-22 04:00PM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics (Business Wire)
Oct-12-22 08:00AM	Pasithea Therapeutics Acquires AlloMek Therapeutics (GlobeNewswire)
07:31AM	EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition (Benzinga)
Oct-10-22 09:39AM	New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope (News Direct)
Oct-03-22 06:03PM	Pasithea Therapeutics to Call Special Meeting of Stockholders (GlobeNewswire)
09:09AM	Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis (News Direct)
Sep-28-22 09:00AM	Investor Group Sends Letter to Pasithea Therapeutics Board of Directors (Business Wire)
Sep-20-22 08:00AM	Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors (GlobeNewswire)
Sep-15-22 08:00AM	Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz (GlobeNewswire)
Sep-12-22 11:53AM	Here's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation (Simply Wall St.)
Sep-09-22 10:32AM	Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Lawrence J. Steinman on May 12, 2020 and is headquartered in Miami Beach, FL.

M.D.Dr. Lawrence Steinman BA

Ph.D.Dr. Tiago Reis Marques M.D.

Chief Financial OfficerMr. Daniel H. Schneiderman

Ph.D.Dr. Kartik Krishnan M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coastlands Capital LP	10% Owner	Jun 17 '26	Buy	0.53	100,000	53,000	3,835,035	Jun 22 10:30 AM
STEINMAN LAWRENCE	Director	Nov 28 '25	Buy	0.75	133,333	100,000	199,691	Dec 01 09:07 AM
Marques Tiago	Chief Executive Officer	Nov 28 '25	Buy	0.75	33,333	25,000	73,334	Dec 01 08:56 AM
Dumesnil Simon	Director	Nov 28 '25	Buy	0.75	33,333	25,000	35,833	Dec 01 08:54 AM

ADIL

Adial Pharmaceuticals Inc

KTTA

Pasithea Therapeutics Corp

Upgrade your Finviz experience